The infrastructure of living medicine

The pharmaceutical industry is shifting from traditional chemistry toward "living drugs." These are therapies where human cells are extracted, modified, and re-infused into patients. This process, known as cell and gene therapy (CGT), presents a logistical and manufacturing burden that most drug developers are not equipped to handle alone. Cellex is a company built specifically to manage this complexity. Founded in 2001 and headquartered in Germany, the company operates as a full-service Contract Development and Manufacturing Organization (CDMO) for the CGT sector.

At its core, Cellex acts as the outsourced factory and supply chain manager for biotechnology startups, larger pharmaceutical firms, and academic researchers. Their work covers the entire "vein-to-vein" cycle, beginning with the collection of starting materials. This initial stage is performed through apheresis, where specific components like leukopaks (concentrated white blood cells) are harvested from either healthy donors or the patients themselves. Cellex maintains its own collection centers and a diverse donor pool, providing a reliable source of cellular material that serves as the foundation for therapy production.

Manufacturing and regulatory expertise

Once the material is collected, it moves into highly regulated manufacturing environments. Cellex operates Good Manufacturing Practice (GMP) facilities where cellular subsets are separated, genetically modified, and cryopreserved. These processes are necessary for the creation of Advanced Therapy Medicinal Products (ATMPs), which include autologous therapies (using the patient's own cells) and allogeneic therapies (using donor cells). The technical requirements here are immense, involving the use of viral vectors or lipid nanoparticles (LNPs) to alter the cellular genetic code. By providing these facilities as a service, Cellex enables its clients to scale clinical trials without the massive capital expenditure required to build their own cleanrooms.

One of the most significant barriers in biotech is the regulatory divide between Europe and North America. Cellex manages this by offering specialized "tech transfer" services. This involves adapting manufacturing protocols developed in one region—such as the United States—to meet the legal and technical standards of the European Medicines Agency (EMA) and local EU regulators. This role as a regulatory bridge is critical for global drug commercialization, ensuring that a process used in a Phase I trial in Boston can be legally replicated for a Phase III trial in Dresden.

Logistics and chain of custody

Because cell therapies are living products, they are highly sensitive to time and temperature. Cellex integrates its manufacturing with a specialized supply chain and logistics arm. They manage the transport of frozen or fresh cellular materials across international borders, ensuring that the chain of identity and chain of custody remain unbroken. In an industry where a single lost or damaged sample can mean the failure of a patient's treatment, this rigorous tracking is the company's primary operational moat. While the current search data shows no evidence of Cellex building AI-native agent tools, the company represents the physical and biological infrastructure that future AI systems in life sciences will eventually need to orchestrate.